Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60000 participants
OBSERVATIONAL
2021-08-01
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All data will be extracted from the hospital electronic database. The investigators will evaluate demographic, clinical and laboratory data, including age, sex, serum creatinine (sCr), sodium and electrolytes, intensive care unit (ICU) admission, length of hospital stay, death, comorbidities and primary diagnosis codes at the hospital discharge (using International Classification of Diseases-ICD-9- codes).
The investigators will include also patients affected by Coronavirus disease 19 (COVID-19).
The primary endpoint will be to describe AKI epidemiology, secondary endpoints will be to evaluate AKI-related risk factors and clinical outcomes, such as length of stay and mortality.
Moreover, the investigators will describe the differences in the outcome and treatments of AKI patients in the medical wards and ICU.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients admitted to University Hospital San Martino, Genova, Italy
Adult patients admitted to University Hospital San Martino, Genova, Italy
Data collection
Collection and analysis of data related to AKI epidemiology, treatment and outcomes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data collection
Collection and analysis of data related to AKI epidemiology, treatment and outcomes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* We'll include also patients affected by Coronavirus disease 19 (COVID-19).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ospedale Policlinico San Martino
OTHER
Universita degli Studi di Genova
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pasquale Esposito
Professor of Nephrology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pasquale Esposito, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Genova, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Policlinico San Martino
Genova, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CER Liguria: 515/2020
Identifier Type: -
Identifier Source: org_study_id